Asian Pacific Journal of Cancer Prevention

  • 제16권2호
  • /
  • Pages.595-600
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Metformin Association with Lower Prostate Cancer Recurrence in Type 2 Diabetes: a Systematic Review and Meta-analysis

  • Hwang, In Cheol (Department of Family Medicine, Gachon University Gil Medical Center) ;
  • Park, Sang Min (Department of Family Medicine and Biomedical Sciences, Seoul National University College of Medicine) ;
  • Shin, Doosup (Department of Education and Research, Seoul National University College of Medicine) ;
  • Ahn, Hong Yup (Department of Statistics, Dongguk University) ;
  • Rieken, Malte (Department of Urology, University Hospital Basel) ;
  • Shariat, Shahrokh F. (Department of Urology, Medical University of Vienna)
  • 발행 : 2015.02.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Accumulating evidence suggests that metformin possesses anticarcinogenic properties, and its use is associated with favorable outcomes in several cancers. However, it remains unclear whether metformin influences prognosis in prostate cancer (PCa) with concurrent type 2 diabetes (T2D). Materials and Methods: We searched PubMed, EMBASE, and the Cochrane Library from database inception to April 16, 2014 without language restrictions to identify studies investigating the effect of metformin treatment on outcomes of PCa with concurrent T2D. We conducted a meta-analysis to quantify the risk of recurrence, progression, cancer-specific mortality, and all-cause mortality. Summary relative risks (RRs) with corresponding 95% confidence intervals (CIs) were calculated. Publication bias was assessed by Begg's rank correlation test. Results: A total of eight studies fulfilled the eligibility criteria. We found that diabetic PCa patients who did not use metformin were at increased risk of cancer recurrence (RR, 1.20; 95%CI, 1.00-1.44), compared with those who used metformin. A similar trend was observed for other outcomes, but their relationships did not reach statistical significance. Funnel plot asymmetry was not observed among studies reporting recurrence (p=0.086). Conclusions: Our results suggest that metformin may improve outcomes in PCa patients with concurrent T2D. Well-designed large studies and collaborative basic research are warranted.

키워드

참고문헌

  1. Allott EH, Abern MR, Gerber L, et al (2013). Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis, 16, 391-7. https://doi.org/10.1038/pcan.2013.48
  2. Azvolinsky A (2014). Repurposing to fight cancer: the metformin-prostate cancer connection. J Natl Cancer Inst, 106, dju030. https://doi.org/10.1093/jnci/dju030
  3. Bansal D, Bhansali A, Kapil G, et al (2013). Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis, 16, 151-8.
  4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  5. Ben Sahra I, Laurent K, Giuliano S, et al (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res, 70, 2465-75. https://doi.org/10.1158/0008-5472.CAN-09-2782
  6. Ben Sahra I, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86. https://doi.org/10.1038/sj.onc.1211024
  7. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M (2005). Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health, 5, 36. https://doi.org/10.1186/1471-2458-5-36
  8. Bonanni B, Puntoni M, Cazzaniga M, et al (2012). Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol, 30, 2593-600. https://doi.org/10.1200/JCO.2011.39.3769
  9. Casa AJ, Dearth RK, Litzenburger BC, et al (2008). The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci, 13, 3273-87.
  10. Conteduca V, Di Lorenzo G, Bozza G, et al (2013). Metabolic syndrome as a peculiar target for management of prostate cancer patients. Clin Genitourin Cancer, 11, 211-20. https://doi.org/10.1016/j.clgc.2013.04.009
  11. Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77. https://doi.org/10.1007/s00125-009-1440-6
  12. Currie CJ, Poole CD, Jenkins-Jones S, et al (2012). Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care, 35, 299-304. https://doi.org/10.2337/dc11-1313
  13. Decensi A, Puntoni M, Goodwin P, et al (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila), 3, 1451-61. https://doi.org/10.1158/1940-6207.CAPR-10-0157
  14. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  15. Emami Riedmaier A, Fisel P, Nies AT, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci, 34, 126-35. https://doi.org/10.1016/j.tips.2012.11.005
  16. Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. https://doi.org/10.1136/bmj.38415.708634.F7
  17. Freedland SJ, Aronson WJ (2009). Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol, 19, 263-7. https://doi.org/10.1097/MOU.0b013e328329ea6c
  18. Garcia JA, Danielpour D (2008). Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther, 7, 1347-54. https://doi.org/10.1158/1535-7163.MCT-07-2408
  19. Giovannucci E, Harlan DM, Archer MC, et al (2010). Diabetes and cancer: a consensus report. CA Cancer J Clin, 60, 207-21. https://doi.org/10.3322/caac.20078
  20. He XX, Tu SM, Lee MH, Yeung SC (2011). Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol, 22, 2640-5. https://doi.org/10.1093/annonc/mdr020
  21. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  22. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11. https://doi.org/10.1158/0008-5472.CAN-09-2994
  23. Jiralerspong S, Palla SL, Giordano SH, et al (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 27, 3297-302. https://doi.org/10.1200/JCO.2009.19.6410
  24. Kaushik D, Karnes RJ, Eisenberg MS, et al (2014). Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol, 32, 1-7. https://doi.org/10.1016/j.urolonc.2013.08.027
  25. Landman GW, Kleefstra N, van Hateren KJ, et al (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 33, 322-6. https://doi.org/10.2337/dc09-1380
  26. Li C, Zhao G, Okoro CA, et al (2013). Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: findings from the 2009 behavioral risk factor surveillance system. Diabetes Care, 36, 1569-76. https://doi.org/10.2337/dc12-1432
  27. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5. https://doi.org/10.2337/dc08-2175
  28. Margel D, Urbach DR, Lipscombe LL, et al (2013). Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol, 31, 3069-75. https://doi.org/10.1200/JCO.2012.46.7043
  29. Niraula S, Dowling RJ, Ennis M, et al (2012). Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat, 135, 821-30. https://doi.org/10.1007/s10549-012-2223-1
  30. Niraula S, Pond G, de Wit R, et al (2013). Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J, 7, 74-81.
  31. Patel T, Hruby G, Badani K, et al (2010). Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology, 76, 1240-4. https://doi.org/10.1016/j.urology.2010.03.059
  32. Peehl DM, Stamey TA (1986). Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol, 22, 82-90. https://doi.org/10.1007/BF02623537
  33. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28. https://doi.org/10.1038/nrc2536
  34. Pollak MN (2012). Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov, 2, 778-90. https://doi.org/10.1158/2159-8290.CD-12-0263
  35. Rieken M, Kluth LA, Xylinas E, et al (2014). Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol, 32, 999-1005. https://doi.org/10.1007/s00345-013-1171-7
  36. Sarma AV, Jaffe CA, Schottenfeld D, et al (2002). Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology, 59, 362-7. https://doi.org/10.1016/S0090-4295(01)01546-1
  37. Sciacca L, Vigneri R, Tumminia A, et al (2013). Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis, 23, 808-15. https://doi.org/10.1016/j.numecd.2013.05.006
  38. Sikka S, Chen L, Sethi G, Kumar AP (2012). Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Res, 2012, 968040.
  39. Snyder CF, Stein KB, Barone BB, et al (2010). Does pre-existing diabetes affect prostate cancer prognosis? a systematic review. Prostate Cancer Prostatic Dis, 13, 58-64. https://doi.org/10.1038/pcan.2009.39
  40. Song CW, Lee H, Dings RP, et al (2012). Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep, 2, 362.
  41. Spratt DE, Zhang C, Zumsteg ZS, et al (2013). Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol, 63, 709-16. https://doi.org/10.1016/j.eururo.2012.12.004
  42. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA, 283, 2008-12. https://doi.org/10.1001/jama.283.15.2008
  43. Suissa S, Azoulay L (2012). Metformin and the risk of cancer:

피인용 문헌

  1. Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases vol.13, pp.1, 2015, https://doi.org/10.1186/s12967-015-0746-z
  2. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6973
  3. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer vol.56, pp.9, 2015, https://doi.org/10.4111/kju.2015.56.9.630
  4. Metformin and Ara-a Effectively Suppress Brain Cancer by Targeting Cancer Stem/Progenitor Cells vol.9, pp.1662-453X, 2015, https://doi.org/10.3389/fnins.2015.00442
  5. Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis vol.48, pp.9, 2016, https://doi.org/10.1007/s11255-016-1316-x
  6. Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1 vol.21, pp.9, 2017, https://doi.org/10.1111/jcmm.13109
  7. Metformin: A Bridge between Diabetes and Prostate Cancer vol.7, pp.2234-943X, 2017, https://doi.org/10.3389/fonc.2017.00243
  8. Prognostic value of metformin for non-small cell lung cancer patients with diabetes vol.16, pp.1, 2018, https://doi.org/10.1186/s12957-018-1362-1